Akebia Therapeutics Inc (AKBA) 옵션

$AKBA: Nuttssssssssssssssssssssss


Whats the deal here...... now $2.80

Someone wanna shed some light on this ???

GO $AKBA

ALKB FDA APPROVED BIO BEAST

AKBA READY FOR 3 BUCKS

AKBA WEEKLY BREAK OUT

AKBA...............................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783

AKBA BREAKING above 2.00 bio beast setting up

Wow. After that update somebody finally got this one figured out. It's going 5 to 10 dollars this year. Then, depending on the progress and outcome of the next trial start again August of 2025, we're talking 20 - 30 Dollars or more in 2026 and 27.

AKBA under $2

AKBA test that 2.50 from a year ago

AKBA breaking out

AKBA....................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783

akba........................https://stockcharts.com/h-sc/ui?s=akba&p=W&b=5&g=0&id=p86431144783

AKBA.............................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783

AKBA.................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783

AKBA.....................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783

AKBA BIO BEAST INTO FDA

AKBA BEASTING LONG...FDA APPROVED DRUG COMES TO MARKET IN JAN

AKBA BUILDING 1.79 BREAK IS COMING

AKBA GAPPING AND READY FOR 1.79

AKBA BACK IN PLAY UNTIL JAN 2025...FDA COMING

AKBA.....................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783

AKBA................................https://stockcharts.com/h-sc/ui?s=ARKB&p=W&b=5&g=0&id=p86431144783

AKBA......................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783

AKBA...........................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783

I believe the current news releases may have answered your question. GLTA

Why do you say we have a gold mine here ?

Toofuzzy

There's no doubt we have a gold mine here, and at some point it will be load up time. Figuring out when is the big question!

SCARY MOVIE

https://journey.ct.events/view/a825b116-e5ee-4e76-ad8d-2e9e9116aa21 tomorrows web cast

added 2k@ 1.11

AKBA................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783

AKBA under $2

ask is stacked! someone needs to slap it.

$AKBA RELOAD

Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.

Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.

I'm in at 33 cents so I'm not going anywhere, just gonna let it ride wherever it goes

Thanks, I’m hanging onto it . With actual revenues of 40-60 mill the last 5 quarters, one would think this stock price should rise. I wouldn’t mind seeing them bought out.

Classic sell the news. Probable offering coming next week to dilute on the good news.

Something just isnt right here. How do you get FDA approval for a drug and your stock price tank? Is there some bads news getting ready to come out on this company??

Long solid position here!

Long term play. Congrats all!

Something didn’t look good , I guess!

AKBA should see 3 bucks

AKBA...FDA EXPLOSION ...WE LOADED THIS BEAUTY....KOCKED AND LOADED!!!!

AKBA...................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783

AKBA new 52 hi

$AKBA looking good damn! she fine.

AKBA.................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783

$AKBA from stocktwits FDA’S THREE ALARM FIRE- (a)FDA issued CRL to FibroGen & Roxadustat (Aug. 2021); (b)FDA issued CRL to Akebia & Vadadustat (March 2022); (c)FDA’s Cardiovascular & Renal Drugs Advisory Committee supported GSK’s Daprodustat for dialysis dependent patients w/ anaemia of CKD w/ 13-3 vote (Oct. 2022); (d)Akebia submitted FDRR w/ FDA’s Senior Advisor in agency’s Office of New Drugs (OND) (Nov. 2022); (e)CKD community & key opinion leaders such as Dr. Jay Wish criticize FDA decision making concerning HIF-PHI drugs (March 2022 - present). (FDA knows from data that Daprodustat is inferior to Vadadustat.) FDA’S RESPONSE TO FIRE - (a)FDA met w/ Akebia to discuss appeal & subsequently requested “additional clarifying information” (not ADCOM, not clinical trial, not denial) (Nov. 2022); (b)FDA assigned Dr. Peter Stein, M.D., Director of OND as deciding authority for appeal (Feb. 2023); (c)Dr. Stein provided Akebia/Vadadustat w/ clear path forward to approval (May 2023). GLTA